One of the biggest questions people have about the Wegovy pill (oral Semaglutide) is whether the weight loss results live up to the hype. The good news is that clinical trials have been promising, with participants losing around 13.6–16.6% of their starting body weight on average (1).
But not everyone responds in the same way, especially when looking at real-world results outside of tightly controlled clinical trials. The amount of weight you lose can be influenced by factors like your dose, lifestyle, how long you stay on treatment, and your body’s response to Semaglutide.
In this article, we'll look at the latest clinical trial data, what the results mean in kilograms, and how much weight you could realistically expect to lose in real life.
Complete an online consultation or visit the Wegovy pill page for more information.
In this article:
What weight loss results were seen in clinical trials?
Did everyone lose the same amount of weight?
What does this mean in kilograms?
How quickly does this weight loss happen?
What could this look like in the real world?
Does taking a higher dose lead to more weight loss?
How can you maximise weight loss on the Wegovy tablet?
What weight loss results were seen in Wegovy pill clinical trials?
The most important study on the Wegovy tablet is the OASIS 4 trial (1).
When looking at the study, you might see two different figures representing the average weight loss achieved by participants:
The treatment policy estimated: 13.6%
The trial product estimated: 16.6%
The treatment policy estimated (13.6%) includes everyone who started treatment, regardless of whether they stopped treatment, missed doses, or didn’t follow administration guidelines correctly.
The trial product estimated measures the effect if all participants had adhered to treatment as assigned, for the full duration. Among those who took the pill exactly as prescribed throughout the study, average weight loss reached 16.6%, which is broadly similar to the weight loss seen with Wegovy pill vs Wegovy injections (2).
Understanding both these figures gives you a good range of how much weight loss is possible, between 13.6%–16.6%, depending on whether treatment is adhered to completely or if there are any complications with treatment.
Did everyone lose the same amount of weight on the Wegovy Pill?
No, the percentages above are trial averages, which means some participants lost less weight while others lost substantially more. Researchers therefore also looked at how many participants achieved specific weight loss milestones (1):
90% lost at least 5% of their starting body weight
70% lost at least 10% of their starting body weight
50% lost at least 15% of their starting body weight
25% lost at least 20% of their starting body weight
There are many reasons why weight loss results with Wegovy tablets vary between individuals, even within tightly-controlled clinical trials, including genetics, metabolism, underlying health conditions, lifestyle habits, and individual response to treatment.
The most important takeaway is that while results vary, most participants (90%) achieved clinically meaningful weight loss of 5% of starting weight, as defined by NICE.
What do the Wegovy pill results mean in kilograms?
People with a higher starting weight typically lose more kilograms overall, even when the percentage of weight lost is the same. This is why clinical trials usually report weight loss as a percentage rather than kilograms.
But most people want to understand what those numbers could look like on the scales.
Using the results from OASIS-4, here is what weight loss could look like at different starting weights:
Starting weight | 13.6% weight loss | 16.6% weight loss |
|---|---|---|
90kg | 12.2kg | 14.9kg |
100kg | 13.6kg | 16.6kg |
120kg | 16.3kg | 19.9kg |
140kg | 19.0kg | 23.2kg |
The 13.6% column reflects the average weight loss achieved across everyone who started treatment, while the 16.6% column reflects the average achieved by participants who remained on treatment and took the Wegovy tablet as prescribed throughout the study.
How quickly does weight loss happen on the Wegovy Pill?
The Wegovy tablet causes gradual weight loss rather than delivering overnight results. In the OASIS 4 trial, the average weight loss figures of 13.6% and 16.6% were achieved after 64 weeks of treatment, or just over a year (1).
Weight loss is often slowest during the first few months because treatment begins at a low dose to help the body adjust to the medicine and lower the risk of side effects and it’s important to understand what to expect in your first months on GLP-1 medication. But as the dose rises in line with the Wegovy Pill dosing guidelines, appetite suppression and weight loss effects become more noticeable.
However, some people do see faster results early on. In a post hoc analysis* of OASIS 4, around 29% of participants lost at least 10% of their body weight within the first 16 weeks, the point at which dose escalation ends (5). These early responders went on to reach an average total weight loss of 21.6% by week 64, higher than the trial average (5).
Participants who did not meet this early threshold still achieved a meaningful average weight loss of 11.5% by the same point (2). This suggests that a slower start does not mean the treatment isn't working, and both faster and slower responders can see substantial results over the full course of treatment.
For this reason, the Wegovy tablet is best viewed as a long-term treatment rather than a quick fix. While many people hope to lose weight as quickly as possible, slower and more gradual weight loss is often easier to maintain over time.
*Analysis that looks back at the results of a study after it's finished to find patterns not initially planned for in the original study.
If you are worried about why you are not losing weight yet and whether your GLP-1 is working, visit our guide.
Complete an online consultation or visit the Wegovy pill page for more information.
What could taking the Wegovy Pill look like in the real world?
Clinical trials are tightly controlled and provide a great indication of how effective weight loss tablets can be, but real-world weight loss is often slightly lower than trial averages.
In two real-world studies that looked at people taking Semaglutide injections (Wegovy injections) or Tirzepatide (Mounjaro injections), the results seen in the real world were less than those seen in trials like SURMOUNT-1 and STEP-1.
At the six-month mark, a clinical study showed Semaglutide users in routine clinical practice lost an average of 10.9% of their body weight, compared with 13.8% in the STEP-1 trial at the same timepoint (8). Tirzepatide users saw a similar pattern, losing 11.9% on average in the real world study versus 13.3–14.5% in SURMOUNT-1 (7). In both cases, the gap between trial and real-world results is likely attributed to differences in dose titration, adherence, and the level of structured lifestyle support that clinical trial participants receive but real-world patients often don't.
Trial (6 months) | Trial (6 months) | Gap | |
|---|---|---|---|
Semaglutide | 13.8% (STEP-1) | 10.9% (8) | ~2.9% |
Tirzepatide | 3.3–14.5% (SURMOUNT-1) | 11.9% (7) | ~1.4–2.6% |
Using these real-world vs clinical trial as examples, it is likely that real-world results of the Wegovy Pill will also vary from the OASIS-4 trial data.
Lifestyle also plays a role. In clinical trials, oral Semaglutide was prescribed alongside dietary advice and increased physical activity. The medication can make it easier to eat less by reducing appetite, cravings, and food noise, but understanding what to eat with Wegovy and how to maintain regular exercise is essential for weight loss.
The Wegovy tablet's trial results show this to some extent: those who remained on treatment and took the medication as prescribed lost an average of 16.6% of their body weight, the average across everyone who started treatment, including those who stopped early, was 13.6% (1).
The takeaway is simple: real-world results can match those seen in clinical trials. But people who stop treatment early, remain on lower doses, or don’t make healthy lifestyle changes often won’t lose weight to the same extent.
Does taking a higher dose of the Wegovy Pill lead to more weight loss?
In general, higher doses of the Wegovy tablet tend to produce more weight loss. But this doesn’t mean everyone will reach the highest possible dose.
Some people achieve meaningful results on lower doses, while others are unable to tolerate stronger tablets because of side effects. Others do complete the full titration schedule without issues. The right maintenance dose is ultimately the one that works for your body.
That said, it's important that weight loss expectations align with the dose you're taking. The OASIS 4 study was conducted on patients who reached the highest dose of 25mg after dose escalation, so if you do not reach the highest dose, it’s important to understand that you might not achieve the same weight loss results as achieved in the study (13.6-16.6%).
However, there are also other things that you can do to help you get the best possible results.
How can you maximise weight loss on the Wegovy pill?
While no one can guarantee how much weight you'll lose, you’ll generally lose more weight if you:
Take the tablet exactly as prescribed. The Wegovy tablet has specific administration guidelines on how to take the Wegovy pill correctly that affect how well it is absorbed.
Stay on treatment where possible. Clinical trials and real-world studies consistently show that people who remain on treatment tend to lose more weight than those who stop early.
Focus on sustainable dietary changes. The Wegovy tablet can reduce appetite and cravings, but weight loss still depends on maintaining a calorie deficit over time.
Stay physically active. Regular exercise can support weight loss, improve overall health, and help preserve muscle mass during treatment.
Think long term. The biggest weight loss results were achieved after more than a year of treatment, not after a few weeks or months.
That said, the most important goal isn't necessarily to achieve the highest possible percentage weight loss, but to make meaningful improvements to your health that you can maintain. Comparing your results to someone else's is rarely helpful. Everyone’s weight loss journey is unique.
If you’re wondering what results you could realistically expect from the Wegovy tablet, complete an online consultation with Oxford Online Pharmacy. Our prescribers can discuss your weight loss goals and explore which weight loss tablet may be most suitable for you.
Complete an online consultation or visit the Wegovy pill page for more information.
You can sign up for our mailing list for 10% off your first order and ongoing discounts | ||
References
Wharton S, Ildiko Lingvay, Bogdanski P, Duque R, Jacob S, Karlsson T, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025 Sep 17;393(11):1077–87.
Wilding JPH, Batterham RL, Calanna S. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine [Internet]. 2021 Feb 10;384(11):989–1002.
Gasoyan H, Butsch WS, Schulte R, Casacchia NJ, Le P, Boyer CB, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025 Jun 10;
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine [Internet]. 2022 Jun 4;387(3):205–16.
Garvey WT, Birkhan O, Naveen R, et al. Early Responders to Oral Semaglutide 25 mg: A Post Hoc Analysis of the OASIS 4 Trial. Poster presented at the European Congress on Obesity (ECO) 2026; 12–15 May 2026; Istanbul, Türkiye.
Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity. 2025.
Hankosky ER, Chinthammit C, Meeks A, Huang A, Ward JM, Mojdami D, Gibble TH. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database. Diabetes, Obesity and Metabolism. 2025.
Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Network Open. 2022;5(9):e2231982. doi:10.1001/jamanetworkopen.2022.31982